Background: DrrAB is dedicated to export of doxorubicin in Streptomyces peucetius, an organism that produces this anticancer drug. Whether this prototype system can export other drugs has not been investigated. Results: DrrAB exports multiple drugs efficiently. Conclusion: Substrate specificity of DrrAB overlaps with known bacterial and human multidrug resistance proteins. Significance: This study suggests common mechanisms and origin for DrrAB and other MDR proteins.

Multi drug resistant Acinetobacter lwoffii infection is increasing particularly in premature and very low-birth weight neonates. Judicious and timely antibiotic use in NICUs are one of the important key in controlling multi-drug resistant Acinetobacter infection and improving clinical outcome.

The testing of the newer therapeutic agents like fosfomycin will add on to therapeutics for UTI's.

No abstract

No abstract